ESMO Preceptorship on Hereditary Cancer Genetics Lugano April 2019

26 - 27 Apr 2019

Lugano, Switzerland

ESMO Preceptorship on Hereditary Cancer Genetics square

Presentations from all ESMO Preceptorship courses are open to all according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.

The use of these presentations is for personal educational purposes only.

Meeting programme | Next/upcoming meetings

The First ESMO Preceptorship on Hereditary Cancer Genetics, focusing on multidisciplinary management, standards of care and future perspectives.

Learning objectives:

To learn about the best clinical practice in the multidisciplinary management of hereditary cancer syndromes
To understand the molecular basis and heterogeneity of the genetic susceptibility to develop cancer
To learn how to recognize, diagnose, treat and provide prevention recommendations to patients with a germline genetic susceptibility

Hide

There are 35 resources available

27 Apr 2019

Conclusion and Farewell

Presenter: J. Balmaña, ES

Session: Session 6 Organisational Models and European Reference Network (ERN)

Resources:

27 Apr 2019

ERN GENTURIS and Finding All Hereditary Cancer

Presenter: N. Hoogerbrugge, NL

Session: Session 6 Organisational Models and European Reference Network (ERN)

Resources:

27 Apr 2019

Tumour Testing Versus Germline Testing

Presenter: M. Ligtenberg, NL

Session: Session 6 Organisational Models and European Reference Network (ERN)

Resources:

27 Apr 2019

Models of Genetic Counselling in Cancer

Presenter: N. Hoogerbrugge, NL

Session: Session 6 Organisational Models and European Reference Network (ERN)

Resources:

27 Apr 2019

Participant Clinical Case Discussion: Targeted Therapies in Epithelial Ovarian Cancer: not only BRCA

Presenter: G. Pavone, IT

Session: Session 5 Hereditary Breast and Ovarian Cancer

Resources:

27 Apr 2019

Participant Clinical Case Discussion: BRCA Mutation Testing in Ovarian Cancer

Presenter: H. Hockings, UK

Session: Session 5 Hereditary Breast and Ovarian Cancer

Resources:

27 Apr 2019

Participant Clinical Case Discussion: Young Early Breast Cancer Patient with PALB2 Mutation

Presenter: I. Bozovic Spasojevic, SRB

Session: Session 5 Hereditary Breast and Ovarian Cancer

Resources:

27 Apr 2019

Germline Mutations as a Therapeutic Target in Cancer

Presenter: J. Balmaña, ES

Session: Session 5 Hereditary Breast and Ovarian Cancer

Resources:

27 Apr 2019

Incorporating Low-Risk Alleles for Accuracy in Breast Cancer Risk

Presenter: M. Tischkowitz, UK

Session: Session 5 Hereditary Breast and Ovarian Cancer

Resources:

27 Apr 2019

BRCA and Beyond

Presenter: M. Tischkowitz, UK

Session: Session 5 Hereditary Breast and Ovarian Cancer

Resources: